Free analyte QC concept: a novel approach to prove correct quantification of free therapeutic protein drug/biomarker concentrations.

Quantification of free drug concentrations is highly challenging due to the dynamic drug-ligand equilibrium, which may result in incorrect results. Current QC concepts do not adequately cover all of the important influencing factors: the assay itself (format and procedure); the calibration concept; the sample preparation; and the sample storage. Here, we propose a 'free analyte QC concept' that enables quantitative testing of these four factors and, thus, provides best possible proof of correct free drug quantification. The principle of the free analyte QC concept and an example of its application for a free drug assay is described. A comparison of this novel approach with current approaches and how the new concept fits (or does not fit) with current regulatory guidelines is discussed.

[1]  V. Wroblewski,et al.  Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments , 2013, mAbs.

[2]  Bing Kuang,et al.  Therapeutic monoclonal antibody concentration monitoring: free or total? , 2010, Bioanalysis.

[3]  Boris Gorovits,et al.  Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation , 2013, The AAPS Journal.

[4]  E. D. De Palo,et al.  Effects of two different types of exercise on GH/IGF axis in athletes. Is the free/total IGF-I ratio a new investigative approach? , 2008, Clinica chimica acta; international journal of clinical chemistry.

[5]  Yong Huang,et al.  Matrix effect and recovery terminology issues in regulated drug bioanalysis. , 2012, Bioanalysis.

[6]  V. Quarmby,et al.  Free versus total ligand-binding assays: points to consider in biotherapeutic drug development. , 2011, Bioanalysis.

[7]  H. Kim,et al.  Copyright � The Korean Academy of Medical Sciences The Levels of Circulating Vascular Endothelial Growth Factor and , 2006 .

[8]  Tong-Yuan Yang,et al.  Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. , 2013, Bioanalysis.

[9]  Heather Myler,et al.  Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.

[10]  Denise M O'Hara,et al.  Critical ligand binding reagent preparation/selection: When specificity depends on reagents , 2007, The AAPS Journal.

[11]  Valerie Theobald,et al.  Life cycle management of critical ligand-binding reagents. , 2013, Bioanalysis.

[12]  J. Sailstad,et al.  Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. , 2011, Bioanalysis.

[13]  Roger Hayes,et al.  Conference report: 6th GCC focus on LBA: critical reagents, positive controls and reference standards; specificity for endogenous compounds; biomarkers; biosimilars. , 2012, Bioanalysis.

[14]  A. Ahene Application and interpretation of free and total drug measurements in the development of biologics. , 2011, Bioanalysis.

[15]  T. Prueksaritanont,et al.  Theoretical Analysis of Interplay of Therapeutic Protein Drug and Circulating Soluble Target: Temporal Profiles of ‘Free’ and ‘Total’ Drug and Target , 2011, Pharmaceutical Research.

[16]  A. Lucia,et al.  Effects of an endurance cycling competition on resting serum insulin-like growth factor I (IGF-I) and its binding proteins IGFBP-1 and IGFBP-3 , 2001, British journal of sports medicine.

[17]  A. Drake,et al.  Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex. , 2012, Analytical biochemistry.

[18]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[19]  Roland F Staack,et al.  Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification. , 2012, Bioanalysis.

[20]  H. Yoshida,et al.  Matrix effects in clinical immunoassays and the effect of preheating and cooling analytical samples , 2004, Clinical chemistry and laboratory medicine.

[21]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[22]  R. Faggioni,et al.  PK-PD modeling of protein drugs: implications in assay development. , 2011, Bioanalysis.

[23]  Apollon Papadimitriou,et al.  Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. , 2011, Bioanalysis.

[24]  Viswanath Devanarayan,et al.  Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.

[25]  Rafael Ponce,et al.  Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. , 2009, Regulatory toxicology and pharmacology : RTP.

[26]  Jean W Lee,et al.  Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics. , 2009, Bioanalysis.